


What's new this week in Israeli MedTech

31 October to 6 November 2026

A strong Israeli week across funding, exits, hospital AI and clearances abroad: StimCardio raised a large Series A for a wearable AF therapy, TailorMed took a reported quarter billion dollar majority deal, ZOLL Itamar and MeMed both advanced US clearances, Ichilov partnered with Wonderful on AI agents, Sofwave posted profitable growth with China NMPA approval, and Schneider Children's opened Israel's first dedicated pediatric health VC.

1. StimCardio closes a $30M Series A for a wearable atrial fibrillation therapy

Announced on 29 October and widely covered in Israeli and US trade press early this week, Israeli medical device company StimCardio closed an oversubscribed $30 million Series A led by Metis Medtech, with Catalyst Health Ventures, corporate strategics and other new and existing investors. The raise funds the NeuroPulse 2 pivotal study of Rhyvive, an investigational wrist worn median nerve stimulation wearable meant to reduce AF recurrence after catheter ablation, and preparation for an FDA De Novo submission. It matters because a home adjunct to ablation is drawing serious cardiac device capital, and recurrence after ablation remains a stubborn clinical gap.

Source: StimCardio and MobiHealthNews

2. TailorMed takes a GrowthCurve Capital majority investment in a reported ~$250M deal

On 2 November TailorMed announced a majority investment from New York private equity firm GrowthCurve Capital. Calcalist reported the deal at about $250 million, with most existing shareholders expected to sell; the companies did not disclose the figure. The Israeli founded digital health company connects patients to medication access, affordability and adherence support across more than 950 hospitals, 4,700 clinics and 3,100 pharmacies, and says it has helped secure more than $7.4 billion in patient financial assistance since 2020. It matters because a US focused Israeli digital health platform has reached a real exit scale while keeping its Tel Aviv development centre.

Source: TailorMed and Ctech

3. ZOLL Itamar gets FDA 510(k) for PolySense, taking WatchPAT 400 to home PSG

On 2 November ZOLL announced FDA 510(k) clearance for PolySense accessories that expand the WatchPAT 400 from a home sleep apnea test to home polysomnography. Self applied head, cardiac and leg patches record EEG, EOG, EMG, ECG and leg movement, and with the full kit the platform can measure up to 11 channels and 9 parameter categories referenced by the AMA CPT Assistant from 1 January 2027. US availability is planned for

early January 2027. It matters because one of Israel's signature sleep tech platforms, now under ZOLL Itamar, is moving advanced sleep studies out of the lab and into the home.

Source: ZOLL

4. Beckman Coulter wins FDA clearance for Access MeMed BV, the Israeli host response assay

On 3 November Beckman Coulter Diagnostics announced US FDA clearance of Access MeMed BV, developed with Haifa based MeMed. The host response blood test measures TRAIL, IP-10 and CRP to help distinguish bacterial from viral infection in adults and children as young as 90 days, with results in as little as 15 minutes on the DxI 9000 analyzer and also available on Access 2. The assay already held a CE mark from April 2026. It matters because an Israeli host response technology is now sitting on major US lab instruments, which is how antimicrobial stewardship tools actually scale.

Source: Beckman Coulter

5. Ichilov partners with Wonderful to build AI agents inside the hospital

On 3 November Tel Aviv Sourasky Medical Center (Ichilov) announced a strategic partnership with Israeli AI company Wonderful to develop, test and deploy AI agents across clinical, operational and service workflows on Wonderful's operating system, including work toward an agentic medical record. Wonderful recently raised $550 million at a $5 billion valuation. Hospital CEO Prof. Eli Sprecher framed the goal as freeing medical teams' time for patients. It matters because a major Israeli hospital is not only buying AI tools, it is co developing them in a live clinical setting as a model for other systems.

Source: Ichilov and Ynet

6. Sofwave posts $28.5M Q3 revenue (+35%) and China NMPA approval

On 3 November TASE listed Sofwave Medical reported third quarter revenue of $28.5 million, up 35% year over year, with usage fee revenue of $13.3 million (+60%) and IFRS net income of $4.1 million. Nine month revenue reached $82.9 million (+41%). In the same quarter China's NMPA approved the Sofwave System for mid to lower facial wrinkles in adults 22 and older, supported by a 200 subject study in China, with an initial order for 70 systems. It matters because an Israeli founded aesthetics device company is compounding recurring usage revenue while opening one of the largest aesthetic markets.

Source: GlobeNewswire (Sofwave)

7. Schneider Children's opens Israel's first pediatric focused VC with a $20M first close

On 4 November Calcalist reported that Schneider Children's Medical Center, with Clalit, is launching Schneider Children's VC (SCVC), Israel's first fund dedicated to pediatric healthcare innovation. The fund has raised about $20 million in an initial closing toward a $50 million target, has already invested in three companies at $500,000 to $3 million each, and is anchored by Schneider, Clalit, the Dor Group and managing partner Ronen Gadot. It matters because pediatrics still gets a thin slice of life science capital, and tying a hospital, a payer and a fund together can shorten the path from concept to clinic.

Source: Ctech

Gary's take

What stands out for me this week is how Israeli medtech is winning on more than one front at once: fresh device capital for StimCardio, a real digital health exit for TailorMed, and US clearances that put Israeli science on global platforms, as with MeMed on Beckman analyzers and WatchPAT moving into home PSG. On a personal note, I had the privilege of working at Itamar in its early days and opened its first US office with the very first WatchPAT, back when there wasn't even a CPT code and all the societies were against home sleep testing. So seeing WatchPAT move into home PSG today really warms my heart. The Ichilov and Wonderful partnership is also worth watching, because hospitals that co develop AI in the ward, rather than only buying it from outside, will set the bar for everyone else. And Schneider Children's new fund is a reminder that if we want better tools for kids, we have to finance them as a category of their own, not as a smaller version of adult care.

Which of these Israeli stories matters most for your company, and is there an area you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

If you'd like to follow along, you can find us here:

Website: synergenmedtech.com

LinkedIn: linkedin.com/company/100981535

YouTube: youtube.com/@synergenmedtech

Sources note: all items were found through a public web scan of the week and each was checked against the linked original source. Trial edition for the new Saturday Israeli MedTech roundup.